Atlas Antibodies, a developer of novel antibodies, agreed to acquire evitria, an operator of a biotechnology firm, from Afinum and SHS for £170m. “After successfully building and continuously improving our expression platform over the last ten years, we look forward to this next phase in our company’s development. We have only recently started to more actively pursue opportunities on a global basis, and look forward to continuing on this growth journey backed by the team around Atlas Antibodies and Patricia Industries," Christian Eberle, evitria CEO.